Heparin dosing in patients with Impella-supported cardiogenic shock

• Published in: International journal of cardiology Vol. 399; p. 131690
• Main Authors: Vandenbriele, Christophe, M'Pembele, René, Dannenberg, Lisa, Metzen, Daniel, Zako, Saif, Helten, Carolin, Mourikis, Philipp, Ignatov, Denis, Huhn, Ragnar, Balthazar, Tim, Adriaenssens, Tom, Vanassche, Thomas, Meyns, Bart, Panoulas, Vasileios, Monteagudo-Vela, Maria, Arachchillage, Deepa, Janssens, Stefan, Scherer, Clemens, Orban, Martin, Petzold, Tobias, Horn, Patrick, Jung, Christian, Zeus, Tobias, Price, Susanna, Westenfeld, Ralf, Kelm, Malte, Polzin, Amin
• Format: Journal Article
• Language: English
• Published: Netherlands Elsevier B.V 15.03.2024
• Subjects: Bleeding; Heparin; Impella; Major adverse cardiac and cerebrovascular events (MACCE); Percutaneous mechanical circulatory support; aPTT; IABP; Impella; IPTW; MACCE; Bleeding; CS; ACT; ASD; Percutaneous mechanical circulatory support; TIMI; UFH; PCI; pMCS; Major adverse cardiac and cerebrovascular events (MACCE); Heparin; MI; DAPT
• ISSN: 0167-5273; 1874-1754
• DOI: 10.1016/j.ijcard.2023.131690

Impella™ is increasingly used in cardiogenic shock. However, thromboembolic and bleeding events are frequent during percutaneous mechanical circulatory support (pMCS). Therefore, we aimed to explore the optimal anticoagulation regime for pMCS to prevent thromboembolism and bleedings. This hypothesis-generating multi-center cohort study investigated 170 patients with left-Impella™ support. We (A) compared bleeding/thrombotic events in two centers with therapeutic range (TR-aPTT) activated partial thromboplastin time (60–80s) and (B) compared events of these centers with one center with intermediate range aPTT (40–60s). After matching, there were no differences in patients' characteristics. In centers aiming at TR-aPTT, major bleeding was numerically lower with aPTT <60s within 48 h of left-Impella™ support, versus patients that achieved the aimed aPTT of ≥60s [aPTT ≥60s: 22 (37.3%) vs. aPTT<60s 14 (23.7%); Hazard ratio [HR], 0.62 (95%) CI, 0.28–1.38; p = 0.234]. Major cardiovascular and cerebrovascular adverse events (MACCE) did not differ between groups. In comparison of centers, TR-aPTT strategy showed higher major bleeding rates [TR: 8 (47.1%) vs. intermediate range: 1 (5.9%); HR, 0.06 (95%) CI, 0.01–0.45; p = 0.006]. MACCE were lower in the intermediate range aPTT group as well [TR 12 (70.6%) vs. intermediate range 5 (29.4%) HR, 0.32 (95%) CI, 0.11–0.92; p = 0.034]. This pilot analysis showed that lowering UFH-targets in left-Impella™ supported CS patients seems to be a safe and promising strategy for reducing major bleedings without increasing MACCE. This needs to be validated in larger, randomized clinical trials. •Bleeding and thrombotic complications are frequent during ImpellaTM-support.•The optimal anticoagulation strategy during pMCS is currently unknown.•Lower heparine dosage appears to reduce major bleeding without increased thrombotic events.